Cargando…

Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry

[Image: see text] Furin is a human serine protease responsible for activating numerous physiologically relevant cell substrates and is also involved in the development of various pathological conditions, including inflammatory diseases, cancers, and viral and bacterial infections. Therefore, compoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Gitlin-Domagalska, Agata, Dębowski, Dawid, Maciejewska, Aleksandra, Samsonov, Sergey, Maszota-Zieleniak, Martyna, Ptaszyńska, Natalia, Łęgowska, Anna, Rolka, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107917/
https://www.ncbi.nlm.nih.gov/pubmed/37077382
http://dx.doi.org/10.1021/acsmedchemlett.3c00008
_version_ 1785026710849191936
author Gitlin-Domagalska, Agata
Dębowski, Dawid
Maciejewska, Aleksandra
Samsonov, Sergey
Maszota-Zieleniak, Martyna
Ptaszyńska, Natalia
Łęgowska, Anna
Rolka, Krzysztof
author_facet Gitlin-Domagalska, Agata
Dębowski, Dawid
Maciejewska, Aleksandra
Samsonov, Sergey
Maszota-Zieleniak, Martyna
Ptaszyńska, Natalia
Łęgowska, Anna
Rolka, Krzysztof
author_sort Gitlin-Domagalska, Agata
collection PubMed
description [Image: see text] Furin is a human serine protease responsible for activating numerous physiologically relevant cell substrates and is also involved in the development of various pathological conditions, including inflammatory diseases, cancers, and viral and bacterial infections. Therefore, compounds with the ability to inhibit furin’s proteolytic action are regarded as potential therapeutics. Here we took the combinatorial chemistry approach (library consisting of 2000 peptides) to obtain new, strong, and stable peptide furin inhibitors. The extensively studied trypsin inhibitor SFTI-1 was used as a leading structure. A selected monocylic inhibitor was further modified to finally yield five mono- or bicyclic furin inhibitors with values of K(i) in the subnanomolar range. Inhibitor 5 was the most active (K(i) = 0.21 nM) and significantly more proteolytically resistant than the reference furin inhibitor described in the literature. Moreover, it reduced furin-like activity in PANC-1 cell lysate. Detailed analysis of furin–inhibitor complexes using molecular dynamics simulations is also reported.
format Online
Article
Text
id pubmed-10107917
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-101079172023-04-18 Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry Gitlin-Domagalska, Agata Dębowski, Dawid Maciejewska, Aleksandra Samsonov, Sergey Maszota-Zieleniak, Martyna Ptaszyńska, Natalia Łęgowska, Anna Rolka, Krzysztof ACS Med Chem Lett [Image: see text] Furin is a human serine protease responsible for activating numerous physiologically relevant cell substrates and is also involved in the development of various pathological conditions, including inflammatory diseases, cancers, and viral and bacterial infections. Therefore, compounds with the ability to inhibit furin’s proteolytic action are regarded as potential therapeutics. Here we took the combinatorial chemistry approach (library consisting of 2000 peptides) to obtain new, strong, and stable peptide furin inhibitors. The extensively studied trypsin inhibitor SFTI-1 was used as a leading structure. A selected monocylic inhibitor was further modified to finally yield five mono- or bicyclic furin inhibitors with values of K(i) in the subnanomolar range. Inhibitor 5 was the most active (K(i) = 0.21 nM) and significantly more proteolytically resistant than the reference furin inhibitor described in the literature. Moreover, it reduced furin-like activity in PANC-1 cell lysate. Detailed analysis of furin–inhibitor complexes using molecular dynamics simulations is also reported. American Chemical Society 2023-03-15 /pmc/articles/PMC10107917/ /pubmed/37077382 http://dx.doi.org/10.1021/acsmedchemlett.3c00008 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Gitlin-Domagalska, Agata
Dębowski, Dawid
Maciejewska, Aleksandra
Samsonov, Sergey
Maszota-Zieleniak, Martyna
Ptaszyńska, Natalia
Łęgowska, Anna
Rolka, Krzysztof
Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
title Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
title_full Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
title_fullStr Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
title_full_unstemmed Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
title_short Cyclic Peptidic Furin Inhibitors Developed by Combinatorial Chemistry
title_sort cyclic peptidic furin inhibitors developed by combinatorial chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107917/
https://www.ncbi.nlm.nih.gov/pubmed/37077382
http://dx.doi.org/10.1021/acsmedchemlett.3c00008
work_keys_str_mv AT gitlindomagalskaagata cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT debowskidawid cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT maciejewskaaleksandra cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT samsonovsergey cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT maszotazieleniakmartyna cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT ptaszynskanatalia cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT łegowskaanna cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry
AT rolkakrzysztof cyclicpeptidicfurininhibitorsdevelopedbycombinatorialchemistry